Thermo Fisher Scientific has opened a new cGMP plasmid DNA manufacturing facility in California to meet the rapidly growing demand for plasmid DNA-based therapies and vital mRNA-based vaccines.
The 67,000-square-foot facility, located on Thermo Fisher's Carlsbad campus, is part of an ongoing investment strategy to meet global needs for cell and gene therapies and vaccines. Plasmid DNA is increasingly used as a therapeutic agent in gene therapies and certain vaccines.
Thermo Fisher will add more than 150 new roles as manufacturing scales.
Last year, the CDMO announced plans to move into the cell therapy space by opening a development and manufacturing collaboration center in Princeton, New Jersey.
Read the press release
